Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059657 · ClinicalTrials.gov registry record · Phase 3
Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
A Phase 3 study of Peripheral Vascular Disease, sponsored by Tanabe Pharma Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 280
- Enrollment target
- 20
- Study locations
NCT00059657: Completed Phase 3 study of Peripheral Vascular Disease, sponsored by Tanabe Pharma Corporation.
NCT00059657 is a Phase 3 study of Peripheral Vascular Disease that has completed, run by Tanabe Pharma Corporation. The registered enrollment target is 280 participants, roughly in line with the 271-participant average among 25 other Peripheral Vascular Disease trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00059657, a Phase 3 study of Peripheral Vascular Disease, has completed, sponsored by Tanabe Pharma Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 280 participants
- Enrollment target
- 20
- Study locations
Study Summary
Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD); This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.
Conditions Studied
Interventions
- DRUG Ecraprost in lipid emulsion
Study Locations (20)
Other
- - Birmingham
- - Bristol
- - Dundee
- - Hull
- - London
California
- - Glendale
- - Los Angeles
- - San Francisco
Arizona
- - Phoenix
- - Tucson
Florida
- - Pensacola
Illinois
- - Springfield
Kansas
- - Shawnee Mission
Louisiana
- - Kenner
Michigan
- - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2001-08 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
What the finished NCT00059657 record still lists
NCT00059657 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 271-participant average among 25 other Peripheral Vascular Disease trials with a reported enrollment target.
The record links to 1 condition, with Peripheral Vascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Ecraprost in lipid emulsion is the first listed.
NCT00059657 names 20 study sites across 13 states, led by Other, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00059657 about?
NCT00059657 is a clinical study titled "Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease". Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD); This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.
What is the current status of trial NCT00059657?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 280 participants. The study started on 2001-08. Estimated completion is 2005-11.
What conditions does trial NCT00059657 study?
This clinical trial studies the following conditions: Peripheral Vascular Disease.
What interventions are being tested in trial NCT00059657?
The interventions under investigation include: Ecraprost in lipid emulsion (DRUG).
Who is sponsoring clinical trial NCT00059657?
This trial is sponsored by Tanabe Pharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00059657 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Vascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00059657's enrollment target sits among peer trials
280 6th of 25 higher than 20 of 25 other Peripheral Vascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Vascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Mobility After Revascularization in Peripheral Artery Disease
RECRUITING · Phase 3
-
Far Red Light to Improve Functioning in PAD
RECRUITING · NA
-
Leg Exercise Assistive Paddling (LEAP) Therapy for Peripheral Artery Disease
RECRUITING · NA
-
ENhancing Exercise with LIGHT to Improve Functioning in PAD
RECRUITING · NA
-
BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)
ACTIVE NOT RECRUITING · Phase 1
-
RISE: A Clinical Evaluation of the StarClose™ Vascular Closure System
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia